Pyrrolidine Compounds as Potential Lipid-Lowering Therapeutic in Cardiovascular Disease.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2021 Mar 16;12(4):521-523. doi: 10.1021/acsmedchemlett.1c00121. eCollection 2021 Apr 8.
Abstract
摘要
相似文献
1
Pyrrolidine Compounds as Potential Lipid-Lowering Therapeutic in Cardiovascular Disease.吡咯烷化合物作为心血管疾病潜在的降脂治疗药物
ACS Med Chem Lett. 2021 Mar 16;12(4):521-523. doi: 10.1021/acsmedchemlett.1c00121. eCollection 2021 Apr 8.
2
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study.脂质单位中进行的原发性和继发性预防调脂治疗患者的观察性研究：ULFI 研究。
Clin Investig Arterioscler. 2023 Nov-Dec;35(6):272-279. doi: 10.1016/j.arteri.2023.06.002. Epub 2023 Jul 19.
3
Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.更强化的降脂治疗对心血管疾病的疗效：系统评价和荟萃分析。
BMC Cardiovasc Disord. 2020 Jul 13;20(1):334. doi: 10.1186/s12872-020-01567-1.
4
Cholesterol-Lowering Effects of Asperidine B, a Pyrrolidine Derivative from the Soil-Derived Fungus PSU-RSPG178: A Potential Cholesterol Absorption Inhibitor.来自土壤真菌PSU-RSPG178的吡咯烷衍生物阿斯皮啶B的降胆固醇作用：一种潜在的胆固醇吸收抑制剂
Pharmaceuticals (Basel). 2022 Jul 31;15(8):955. doi: 10.3390/ph15080955.
5
The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering.降脂治疗早期与延迟进行心血管疾病一级预防的预期 30 年获益。
Circulation. 2020 Sep;142(9):827-837. doi: 10.1161/CIRCULATIONAHA.120.045851. Epub 2020 Jul 23.
6
Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.比较欧洲和美国指南中的降脂治疗方案在心血管疾病一级预防中的应用。
Eur J Prev Cardiol. 2023 Nov 30;30(17):1856-1864. doi: 10.1093/eurjpc/zwad193.
7
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells.两亲性吡咯烷衍生物对人胰腺癌细胞的细胞杀伤和自噬诱导作用。
Eur J Med Chem. 2018 Apr 25;150:457-478. doi: 10.1016/j.ejmech.2018.02.086. Epub 2018 Mar 2.
8
Lipid-lowering drug use and cardiovascular events after myocardial infarction.心肌梗死后降脂药物的使用与心血管事件
Ann Pharmacother. 2002 May;36(5):751-7. doi: 10.1345/aph.1A308.
9
Drug treatment of hyperlipidemia in women.女性高脂血症的药物治疗
JAMA. 2004 May 12;291(18):2243-52. doi: 10.1001/jama.291.18.2243.
10
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.高胆固醇血症的管理、高心血管风险患者治疗方法的适宜性及新药
High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.
本文引用的文献
1
More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease.更多嘌呤能受体值得作为心血管疾病治疗的治疗靶点引起关注。
Am J Physiol Heart Circ Physiol. 2020 Oct 1;319(4):H723-H729. doi: 10.1152/ajpheart.00417.2020. Epub 2020 Aug 21.
2
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.脂蛋白(a)：拓宽我们对主动脉瓣狭窄的认识。
Trends Cardiovasc Med. 2021 Jul;31(5):305-311. doi: 10.1016/j.tcm.2020.06.001. Epub 2020 Jun 7.
3
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality.心血管疾病中的降脂治疗：从神话到分子现实。
Pharmacol Ther. 2020 Sep;213:107592. doi: 10.1016/j.pharmthera.2020.107592. Epub 2020 May 31.
4
Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives.反义载脂蛋白[a]治疗：现状与未来展望。
Eur J Intern Med. 2020 Jun;76:8-13. doi: 10.1016/j.ejim.2020.04.036. Epub 2020 Apr 24.
5
Recent advances in genome editing for cardiovascular disease.心血管疾病基因组编辑的最新进展。
Curr Opin Cardiol. 2020 May;35(3):242-248. doi: 10.1097/HCO.0000000000000723.
6
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.家族性高胆固醇血症和脂蛋白(a)升高：双重遗传性风险和新的治疗机会。
J Intern Med. 2020 Jan;287(1):2-18. doi: 10.1111/joim.12981.
Zotero 插件